Compare Adaptive Biotechnologies Corp (ADPT) vs HubSpot Inc (HUBS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs HubSpot Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while HubSpot Inc trades at $197.32 (market cap $10.50B). The key difference: HubSpot Inc is far larger — about 3.2× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | HUBS | |
|---|---|---|
Market Cap | $3.33B | $10.50B |
Sector | Health | Technology |
52-Week High | $22.37 | $560.90 |
52-Week Low | $10.24 | $170.39 |
Enterprise Value | $3.19B | $9.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HUBS trades at $205.23, up 6.82% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $188 and resistance at $208. Recent earnings beats and 23% revenue growth in Q1 2026 highlight robust execution. Analyst consensus is overwhelmingly bullish with an 80.85% buy rating and a $273.53 price target, suggesting significant upside from current levels.
Outlook remains positive driven by AI integration and customer growth, but high P/E of 102.02 poses valuation risk. Competition from Salesforce and SaaS sector volatility are key concerns. Net income margin improvement to 3.04% in 2025 signals profitability traction, yet investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
